Bioavailability Profile: Bicalutamide

Bicalutamide (BIC) is a non-steroidal antiandrogen used to treat prostate cancer by blocking androgen receptors in the prostate gland, primarily through its (R)-enantiomer. It is slowly absorbed after oral administration, with absorption being dose-dependent, and is extensively metabolized in the liver. Elimination occurs through renal and hepatic pathways, with BIC and its metabolites excreted in nearly equal amounts in urine and feces. While BIC is effective due to its high selectivity, its adverse effects require careful monitoring. The review details the drug's physicochemical properties, analytical methods, pharmacokinetics, bioavailability, and pharmacology.